Entries by Dan Zapata

La Jolla Pharmaceutical Company Announces Portfolio Reprioritization

May 7, 2015 20:11 UTC Conference Call and Webcast at 8:00 AM Eastern Time on Friday, May 8 SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced a reprioritization of its […]

La Jolla Pharmaceutical Company Announces Additions to LJPC-401 Advisory Board

La Jolla Pharmaceutical Company Announces Additions to LJPC-401 Advisory Board SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the addition of four new members to its advisory board […]

La Jolla Pharmaceutical Company Appoints Dennis Mulroy as Chief Financial Officer

La Jolla Pharmaceutical Company Appoints Dennis Mulroy as Chief Financial Officer SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that Dennis Mulroy will join the Company as Chief […]

La Jolla Pharmaceutical Company Announces Fourth Quarter and Full Year 2014 Financial Results and Corporate Highlights

SAN DIEGO, CA – March 16, 2015 – La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported fourth quarter and full year 2014 financial results and highlighted recent corporate progress and near-term […]